These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: [Comparative study of adriamycin and thiotepa in the chemoprophylaxis of superficial bladder tumors].
    Author: Salinas Sánchez AS, Moreno Avilés J, Pérez Albacete M, Salmerón Lopez-Rua J, Guardiola Más A, Server Falgas G.
    Journal: Actas Urol Esp; 1989; 13(2):99-102. PubMed ID: 2499166.
    Abstract:
    We present a comparative study of the evolution of 250 patients with primary surface tumour, analysing the percentages of relapses and period free of illness according to the type of endovesical chemoprophylactic treatment administered. In 103 cases no chemotherapy treatment at all was administered, whilst in 90 cases thiotepa was applied and in 57 adriamycin. We have studied the evolution of these patients in accordance with the number of tumours, location, cell grade and stage, assessing the progression in grade and state of the primary tumours. After analysing the results, we observe that relapses are significantly more numerous and more precocious in patients receiving no chemotherapy treatment at all, and differences may be seen on an overall basis between adriamycin and thiotepa. In grade 1, stage 0 and single tumours, though they displayed a longer period free of illness in treated patients, the relapses were similar to those of non-treated patients. In this type of tumour thiotepa proved more effective than adriamycin, although the latter provides a longer period free of illness. Patients with high grade and stage tumours do indeed relapse significantly less and later when they receive treatment, and adriamycin achieves better results. As regards location, save in the case of tumours located on the cupula and front face, where relapses were the same between groups of treated and non-treated patients, in the rest the evolution of the tumours was better in treated patients irrespective of location.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]